HCV in Egypt, prevention, treatment and key barriers to elimination

References

• Ministry of Health, Egypt, El-Zanaty and Associates, Egypt, ICF International. Egypt Health Issues Survey. Cairo, Egypt and Rockville, MD, USA: Ministry of Health and ICF International; 2015.
   Google Scholar
• El-Zenati F, Way A. Knowledge and prevalence of Hepatitis C. Egypt demographic and health survey 2008. [ONLINE]. [cited 2017 Oct 10]. Available from: https://dhsprogram.com/pubs/pdf/FR220/FR220.pdf
   Google Scholar
• Strickland G. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology. 2006;43(5):915–922.
   PubMed Web of Science ®Google Scholar
• Rao MR, Naficy AB, Darwish MA, et al. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis. 2002;2:29. 24.
   PubMed Web of Science ®Google Scholar
• Frank C, Mohamed M, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–891.
   PubMed Web of Science ®Google Scholar
• Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553–562.
   PubMed Web of Science ®Google Scholar
• Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: a review. Expert Opin Drug Saf. 2016 Dec;15(12):1643–1652.
   PubMed Web of Science ®Google Scholar
• El Raziky M, Fathalah W, El-Akel W, et al. The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: a single centre Egyptian study. Hepat Mon. 2013;13:e10069.
   PubMed Web of Science ®Google Scholar
• Esmat G, El Kassas M, Hassany M, et al. How to optimize HCV therapy in genotype 4 patients. Liver Int. 2013 Feb;33(Suppl 1):41–45.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Elbaz T, Hafez E. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf. 2016 Dec;15(12):1643–1652.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis C virus infection–egypt, 2001–2012. MMWR Morb Mortal Wkly Rep. 2012;61:545–549.
   PubMedGoogle Scholar
• El-Akel W, El-Sayed MH, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat. 2017 Apr;24(4):262–267.
   PubMed Web of Science ®Google Scholar
• Gomaa A, Allam N, Elsharkawy A, et al. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med. 2017 May;15(9):17–25.
   Google Scholar
• Waked I, Doss W, El-Sayed M, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol. 2014;15(2):45–52.
   PubMed Web of Science ®Google Scholar
• Estes C, Abdel-Kareem M, Abdel-Razek W, et al. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther. 2015;42(6):696–706.
   PubMed Web of Science ®Google Scholar
• Gower E, Estes CC, Hindman S, et al. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol. 2014;61:S45–S57.
   PubMed Web of Science ®Google Scholar
• El Raziky M, Gamil M, Hammad R, et al. Treatment of Hepatitis C genotype 4 patients with simeprevir and sofosbuvir: preliminary results from a phase iia, partially randomised, open-label trial conducted in Egypt (OSIRIS). Abstract ID: 1163. OSIRIS poster, presented at the Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases. 2015.
   Google Scholar
• El-Khayat HR, Fouad YM, Maher M, et al. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. Gut. 2017 Nov;66(11):2008–2012.
   PubMed Web of Science ®Google Scholar
• Waked I, Shiha G, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2016;1(1):36–44.
   PubMed Web of Science ®Google Scholar
• Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18378 patients in Egypt. Aliment Pharmacol Ther. 2017;1–11.
   Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
   PubMed Web of Science ®Google Scholar
• Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol. 2013;58:583–592.
   PubMed Web of Science ®Google Scholar
• Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63(3):581–585.
   PubMed Web of Science ®Google Scholar
• Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62:1040–1046.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment naıve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381:2100.
   PubMed Web of Science ®Google Scholar
• Alessandra M, Valeria P. Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies. Dig Liver Dis. 2014;46:S179–85.
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61:373–395.
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
   PubMed Web of Science ®Google Scholar
• Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465(7294):96–100.
   PubMed Web of Science ®Google Scholar
• Boglione L, Pinna SM, Cardellino CS, et al. Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. Infection. 2017 Feb;45(1):103–106.
   PubMed Web of Science ®Google Scholar
• Moshyk A, Martel MJ, Tahami Monfared AA, et al. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada. J Med Econ. 2016;19(2):181–192.
   PubMed Web of Science ®Google Scholar
• Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol. 2016;pii: S0168-8278(16)30486-X.
   Google Scholar
• Luetkemeyer AF, McDonald C, Ramgopal M, et al. 12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 Study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis. 2016;62(12):1489–1496.
   PubMed Web of Science ®Google Scholar
• Gevers TJ, Burger D, Schipper-Reintjes E, et al. Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients. Neth J Med. 2016;74(5):225–227.
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–1505.
   PubMed Web of Science ®Google Scholar
• Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016 Nov;65(11):1861–1870.
   PubMed Web of Science ®Google Scholar
• Kandeel A, Genedy M, El-Refai S, et al. The prevalence of HCV infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2016;37:45–53.
   PubMed Web of Science ®Google Scholar
• Elsharkawy A, Fouad R, El Akel W, et al. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. Aliment Pharmacol Ther. 2017;45(5):681–687.
   PubMed Web of Science ®Google Scholar
• Elgharably A, Gomaa AI, Crossey MM, et al. Hepatitis C in Egypt - past, present, and future. Int J Gen Med. 2016;20(10):1–6.
   Google Scholar
• Walker CM. Designing an HCV vaccine: a unique convergence of prevention and therapy? Curr Opin Virol. 2017 Apr;23:113–119.
   PubMed Web of Science ®Google Scholar